Tapping the potential of metabolomics, an emerging field focused on the chemical processes of metabolism, researchers at University of California, San Diego School of Medicine have identified a new and pivotal player in diabetic kidney disease.
The study, published online July 22 in the Journal of the American Society of Nephrology, also clarifies a central mechanism of action in diabetic kidney disease that is generating considerable excitement among researchers and the biopharmaceutical community. The mechanism, involving the NADPH (nicotinamide adenine dinucleotide phosphate) oxidase (NOX) proteins, NOX1 and NOX4, is now the subject of a phase II clinical trial for the treatment of diabetic kidney disease. … Read the Full Story from the UC San Diego News Center
Senior author of the study report is Kumar Sharma, MD, FAHA, professor of medicine in the Division of Nephrology and director of the Center for Renal Translational Medicine at UC San Diego School of Medicine.
Read the study report in the Journal of the American Society of Nephrology (UC San Diego Only)